These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36203050)

  • 1. Screening of visceral metastasis in castration-resistant prostate cancer: a cornerstone in personalized patient's care.
    Grobet-Jeandin E; Valerio M
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):3-4. PubMed ID: 36203050
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 3. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
    Filippi L; Frantellizzi V; Chiaravalloti A; Pontico M; De Feo MS; Corica F; Montebello M; Schillaci O; De Vincentis G; Bagni O
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
    N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darolutamide for non-metastatic, castration-resistant prostate cancer.
    Burki T
    Lancet Oncol; 2019 Mar; 20(3):e139. PubMed ID: 30799257
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T
    Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
    Taplin ME; Armstrong AJ; Lin P; Krivoshik A; Phung D; Parli T; Tombal B; Beer TM
    J Urol; 2017 Dec; 198(6):1324-1332. PubMed ID: 28736322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer.
    Lee JS; Lee HS; Ha JS; Han KS; Rha KH; Hong SJ; Chung BH; Koo KC
    J Urol; 2018 Jul; 200(1):114-120. PubMed ID: 29366641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metastatic castration resistant prostate cancer: 2018 perspective.].
    Miñana López B
    Arch Esp Urol; 2018 Sep; 71(8):625-627. PubMed ID: 30319122
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.
    Ahmadzadehfar H; Rahbar K; Essler M; Biersack HJ
    Semin Nucl Med; 2020 Jan; 50(1):98-109. PubMed ID: 31843065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment.
    Mansinho A; Macedo D; Fernandes I; Costa L
    Adv Exp Med Biol; 2018; 1096():117-133. PubMed ID: 30324351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Sep; 196(3):742. PubMed ID: 27597066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.